至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

In vitro cytotoxic effect of Trastuzumab in combination with Pertuzumab in breast cancer cells is improved by interleukin-2 activated NK cells.

Mol Biol Rep. 2019; 
Asgari A,, Sharifzadeh S, Ghaderi A,, Hosseini A, Ramezani A,.
Products/Services Used Details Operation
Proteins, Expression, Isolation and Analysis … Finally, the elution fraction after tube dialysis was evaluated for Endotoxin by the Toxin Sensor Chromogenic LAL Endotoxin Assay Kit (Genscript, Piscataway, NJ, USA) In vitro evaluation of recombinant IL-2 Physicochemical analysis (SDS-PAGE and Western blotting) … Get A Quote

摘要

Targeting erb-b2 receptor tyrosine kinase 2 (ERBB2) using the combination of Trastuzumab and Pertuzumab has demonstrated promising results in breast cancer therapy. It has further been revealed that interleukin-2 (IL-2) can activate Natural Killer cells (NK cells) and elevate their cytotoxic potency against tumor cells. In this study, we explored the cytotoxic effect of recombinant human IL-2 in combination with Trastuzumab and Pertuzumab on the ERBB2 positive (SK-BR-3) and negative (MDA-MB-231) breast cancer cell lines. The cytotoxicity level of IL-2 activated NK cells (approximately 75%) were significantly higher than untreated cells (approximately 55%) in the presence of Trastuzumab and Pertuzumab against S... More

关键词

Breast cancer; Immunotherapy; Interleukin 2; Pertuzumab; Trastuzumab